Please login to the form below

Not currently logged in
Email:
Password:

Takeda and Merck abandon cancer drug

Merck and Takeda are terminating the development of their cancer drug matuzumab after disappointing late-stage trials.

Merck and Takeda are terminating the development of their cancer drug matuzumab after disappointing late-stage trials.

Merck first announced in August 2007 that trial results were not promising, and that it may abandon development of the drug.

A phase II trial investigating matuzumab in combination with irinotecan in patients with mCRC who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity. The companies said at the time that they would continue to study the drug in other tumours including NSCLC.

According to a statement released yesterday (January 18) by Takeda, matuzumab has not met predefined clinical endpoints of activity in phase II clinical trials in indications such as gastric cancer and non-small cell lung cancer (NSCLC).

Takeda entered into a co-development and co-commercialisation agreement for matuzumab with Merck in September 2005, which covered markets including the US, several countries in Europe, Japan and some countries in Asia.

18th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics